Table 2:
Characteristics of POC HbA1c Devices Available for Use in Canada
| Characteristic | A1c Now+ | DCA Vantage Analyzer | In2it (I) System |
|---|---|---|---|
| Manufacturer | Bayer Healthcare LLC | Siemens Healthcare Diagnostics Inc | Bio-Rad Laboratories Deeside |
| Method | Immunoassay | Latex agglutination inhibition immunoassay | Boronate-affinity chromatography |
| Blood sample | 5 μL (capillary or venous) | 1 μL (capillary or venous) | 10 μL (capillary or venous) |
| Time for results | 5 minutes | 6 minutes | 10 minutes |
| Interference with abnormal hemoglobin variants (15) | HbC, HbS, HbF − 10–15% | HbC, HbE, HbF − 10–15% | HbF − 10% |
| NGSP-certified (16) | Yes | Yes | Yes |
| CLIA waived | Yes | Yes | Yes |
| Other characteristics | Same device as A1c Now, with more test cartridges in the kit | Successor of DCA 2000 | N/A |
Abbreviation: CLIA, Clinical Laboratory Improvement Amendments; HbC, hemoglobin C; HbE, hemoglobin E; HbF, hemoglobin F; HbS, hemoglobin S; NGSP, National Glycohemoglobin Standardization Program; POC HbA1c, point-of-care hemoglobin A1c.